NEUROCHEMISTRY INTERNATIONAL, published by Pergamon-Elsevier Science Ltd, offers a premier platform for researchers and professionals in the realms of cell biology and cellular and molecular neuroscience. Established in 1980 and continuing its passion for advancing the field, this esteemed journal enhances scientific collaboration with a notable 2023 Q2 ranking in both relevant categories, placing it among the top-tier publications in its discipline with a Scopus rank of 23/97 for Cellular and Molecular Neuroscience. With its focus on groundbreaking research, the journal provides a wealth of vital data and insights that drive forward our understanding of neurochemistry and its implications in health and disease. While not an Open Access journal, NEUROCHEMISTRY INTERNATIONAL is integral for professionals, academics, and students aiming to stay at the forefront of neurobiological research innovations, making significant contributions to both academia and clinical applications.

European Neurology, published by KARGER, is a distinguished journal in the field of neurology, catering to both clinical and neuroscience specialties. Since its inception in 1897 and continuing through 2024, the journal has been a vital platform for disseminating significant research findings and insights in neurology. With an ISSN of 0014-3022 and E-ISSN of 1421-9913, it ranks in the Q3 quartile in both clinical neurology and general neurology categories, reflecting its commitment to scholarly excellence while holding the 175th rank in clinical medicine and the 93rd in neuroscience, according to Scopus metrics. European Neurology facilitates a deeper understanding of neurological disorders and treatments, appealing to a diverse readership that includes researchers, clinicians, and students alike. Despite not currently offering open access, the journal’s rigorous peer-review process ensures that only high-quality research reaches its audience, making it an essential resource for those looking to stay informed in the rapidly evolving field of neurology.

Alzheimer's Research & Therapy is a leading peer-reviewed journal published by BMC, dedicated to advancing our understanding of Alzheimer's disease and other neurodegenerative disorders. As an Open Access journal since 2009, it ensures that vital research findings are freely accessible to the global community, facilitating collaboration and innovation in the field. The journal's commitment to quality is evident in its impressive impact factor and its prestigious ranking in the Q1 quartile across multiple categories including Cognitive Neuroscience and Neurology. With a Scopus rank placing it in the top tier of both Neuroscience and Neurology disciplines, Alzheimer's Research & Therapy serves as a crucial platform for researchers, clinicians, and students who seek to contribute to the fight against Alzheimer's and related disorders. The journal covers a wide range of topics and actively encourages submissions that explore therapeutic strategies and innovative research methodologies, enriching the scientific dialogue in this vital area of health.

NEUROLOGIA, an esteemed journal published by ELSEVIER ESPANA SLU, stands at the forefront of the field of neurology, with a dedicated focus on innovative research and clinical practice since its inception in 1973. As an Open Access journal since 2017, it champions the dissemination of knowledge, allowing researchers, professionals, and students alike to access cutting-edge findings in neurology without barriers. With an impressive Scopus rank of #115 in the clinical neurology category, placing it in the 71st percentile, NEUROLOGIA is categorized as Q3 in both general medicine and clinical neurology, reflecting its impact and relevance in a rapidly evolving field. Based in Barcelona, Spain, the journal's commitment to advancing understanding of neurological conditions is underscored by its rigorous peer-review process and engagement with a global audience. As it continues to publish vital research that shapes clinical practices and informs policy, NEUROLOGIA remains an integral resource for those striving to improve outcomes in neurology.

NeuroImage-Clinical is a premier open access journal published by Elsevier Science Ltd, dedicated to advancing the field of clinical neuroimaging and its applications in a variety of neurological disorders. With an ISSN of 2213-1582, this journal has established itself as a leading source of innovative research since its inception in 2012, now continuing through 2024. Recognized for its high impact, it occupies the top quartile (Q1) in prestigious categories such as Cognitive Neuroscience, Neurology, and Radiology, affirming its relevance in clinical and research settings. Its Scopus rankings further exemplify its significant contribution to the disciplines of Radiology and Neurology, consistently placing it among the top tiers of journals in these fields. This journal not only provides critical insights for researchers and professionals but also serves as a valuable resource for students, fostering an understanding of the complexities in neuroimaging techniques and their implications for patient care. With open access options ensuring broad dissemination of knowledge, NeuroImage-Clinical plays a pivotal role in enhancing collaboration and innovation within the global neuroscience community.

The Lancet Neurology is a premier academic journal published by Elsevier Science Inc, specializing in the field of neurology. With a robust impact factor that signifies its authoritative presence, it consistently ranks in the Q1 category for clinical neurology according to the 2023 standards, positioning itself as the leading journal in its domain, ranking #1 out of 400 in Scopus' neurology rankings and placing in the 99th percentile. Since its establishment in 2002, it has provided a vital platform for disseminating innovative research and clinical advances related to neurological disorders. The journal’s precise focus includes cutting-edge studies on neurodegenerative diseases, stroke, epilepsy, and neuroimaging, which are essential for advancing clinical practice and improving patient outcomes. While it does not offer open access, readers can find high-impact research published monthly, making it indispensable for practitioners, researchers, and students eager to stay at the forefront of neurological science.

Translational Neurodegeneration, an esteemed journal in the field of neuroscience, is published by BMC and has been an open access platform since 2012, delivering high-quality research from its base in the United Kingdom. With an impressive impact factor reflecting its significant contributions, this journal focuses on critical advancements in cellular and molecular neuroscience, cognitive neuroscience, and clinical neurology, boasting a Q1 ranking across all these categories as of 2023. Researchers and professionals benefit from its extensive reach, characterized by exceptional Scopus rankings that place it in the top percentile of its field. The journal serves as a vital resource for academics and healthcare practitioners alike, aiming to bridge the gap between laboratory discoveries and clinical applications, thereby enhancing understanding and treatment of neurodegenerative diseases. With its commitment to open access, Translational Neurodegeneration ensures that its published research is accessible to a global audience, promoting collaboration and knowledge exchange within the scientific community.

NEUROLOGY, published by Lippincott Williams & Wilkins, stands as a premier journal in the field of neurology, holding an esteemed Q1 category ranking in clinical neurology as of 2023. Established in 1951, this journal has been a critical resource for the dissemination of cutting-edge research and clinical advancements, with an impressive Scopus rank of 24 out of 400, placing it in the 94th percentile among its peers. NEUROLOGY serves as a vital platform for neurologists, researchers, and medical professionals seeking to stay abreast of the latest findings and innovations in the treatment and understanding of neurological disorders. With its rigorous peer-review process and commitment to excellence, NEUROLOGY remains essential reading for all individuals dedicated to advancing the science and practice of neurology, contributing significantly to the ongoing dialogue in this vital area of medicine.

METABOLIC BRAIN DISEASE, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal dedicated to advancing our understanding of the metabolic processes impacting brain health and disease. Established in 1986 and set to continue until 2024, this journal encompasses a wide range of interdisciplinary research that intersects the fields of Biochemistry, Cellular and Molecular Neuroscience, and Neurology, as evidenced by its notable quartile placements in Q2 and Q3 for 2023. With an ISSN of 0885-7490 and an E-ISSN of 1573-7365, it serves as a vital resource for researchers and practitioners aiming to deepen their insights into cerebral metabolic disorders and their implications. Although currently not an Open Access option, its rigorous peer-review process ensures that high-quality, impactful research reaches its audience. Showcasing a significant rank within the top percentile of its categories, METABOLIC BRAIN DISEASE is instrumental in shaping the future of neurological research and clinical applications.

The American Journal of Alzheimer's Disease and Other Dementias, published by SAGE Publications Inc, is a pivotal resource for researchers, clinicians, and students engaged in the study of neurodegenerative diseases, particularly Alzheimer’s disease and various forms of dementia. With an impact factor reflecting its significance in the field, the journal boasts an open-access format since 2020, ensuring that groundbreaking research is accessible to a global audience. The journal holds prestigious Q2 rankings across several categories, including Clinical Psychology, Geriatrics and Gerontology, Neuroscience, and Psychiatry and Mental Health. Covering a wide spectrum from 1986 to 2024, it provides essential insights into innovative treatments, care strategies, and the latest findings in dementia research, solidifying its importance in fostering knowledge and advancing the field. With a commitment to high-quality scholarship, this journal is an indispensable tool for advancing understanding in the dynamic landscape of dementia studies.